ACT China

Clinical trials play a vital role in improving outcomes for cancer patients. In China, The Oncologist's efforts in clinical trial education and communication continue through programs such as ACT China.

The combined forces of the CSCO Foundation (中国临床肿瘤学会基金会), CSCO, and STO developed a clinical trial curriculum covering ethics, preclinical studies, clinical trial design/conduct, statistics, and regulatory considerations. During these meetings, a global faculty of experts addressed the current issues and challenges in executing phase I, II, and III clinical trials, through a series of lectures, discussions, and workshops.

The curriculum was designed by an international steering committee of experts to help transform oncology research in China for the benefit of cancer patients in China and around the world.

Society for Translational Oncology (STO) and The Oncologist  partner with the Chinese Society of Clinical Oncology (中国抗癌协会临床肿瘤学协作专业委员会, CSCO) and the CSCO Foundation (中国临床肿瘤学会基金会) on educational initiatives that address critical health and cancer care issues in China. These efforts serve to foster communication between Chinese physicians and other leaders in oncology practice throughout the world.